HK1204274A1 - 抑制眼部血管生成的方法 - Google Patents

抑制眼部血管生成的方法

Info

Publication number
HK1204274A1
HK1204274A1 HK15104837.2A HK15104837A HK1204274A1 HK 1204274 A1 HK1204274 A1 HK 1204274A1 HK 15104837 A HK15104837 A HK 15104837A HK 1204274 A1 HK1204274 A1 HK 1204274A1
Authority
HK
Hong Kong
Prior art keywords
methods
ocular angiogenesis
inhibiting ocular
inhibiting
angiogenesis
Prior art date
Application number
HK15104837.2A
Other languages
English (en)
Inventor
Harald J Junge
Weilan Ye
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1204274A1 publication Critical patent/HK1204274A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15104837.2A 2008-09-10 2015-05-21 抑制眼部血管生成的方法 HK1204274A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9575708P 2008-09-10 2008-09-10
US10350208P 2008-10-07 2008-10-07
US23451909P 2009-08-17 2009-08-17

Publications (1)

Publication Number Publication Date
HK1204274A1 true HK1204274A1 (zh) 2015-11-13

Family

ID=42005747

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104837.2A HK1204274A1 (zh) 2008-09-10 2015-05-21 抑制眼部血管生成的方法

Country Status (16)

Country Link
US (3) US20100129375A1 (zh)
EP (1) EP2334702A2 (zh)
JP (2) JP5859307B2 (zh)
KR (1) KR20110051245A (zh)
CN (2) CN102149728B (zh)
AU (1) AU2009291747B2 (zh)
BR (1) BRPI0913476A2 (zh)
CA (1) CA2734694A1 (zh)
CL (1) CL2011000513A1 (zh)
HK (1) HK1204274A1 (zh)
IL (2) IL211279A (zh)
MX (1) MX2011002418A (zh)
RU (2) RU2530583C2 (zh)
SG (1) SG193209A1 (zh)
WO (1) WO2010030813A2 (zh)
ZA (1) ZA201101202B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114078B2 (en) * 2009-03-17 2015-08-25 Retinol Solutions Llc Methods and compositions for genetic and retinal disease
CA2862422A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Anti-lrp5 antibodies and methods of use
US20150141340A1 (en) * 2012-06-04 2015-05-21 Yale University Method of treating and preventing ocular angiogenesis
US20150376252A1 (en) * 2013-02-21 2015-12-31 Van Andel Research Institute Norrin Mutant Polypeptides, Methods of Making and Uses Thereof
CN110201144B (zh) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6932506B2 (ja) 2013-11-26 2021-09-08 イエール ユニバーシティ 細胞透過組成物およびそれを用いる方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6796059B2 (ja) * 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｗｎｔシグナリングアゴニスト分子
US10206978B2 (en) 2015-06-08 2019-02-19 Retinal Solutions Llc Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema
US10202429B2 (en) 2015-06-08 2019-02-12 Retinal Solutions Llc Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema
US10669321B2 (en) 2015-06-08 2020-06-02 Retinal Solutions Llc Retinal capillary regeneration with synthetic norrin protein
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
WO2018111099A1 (en) 2016-12-12 2018-06-21 Stichting Vumc Biomarkers and treatments for cerebral amyloid angiopathy (caa)
RU2669787C2 (ru) * 2016-12-13 2018-10-16 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Средство для лечения заболевания, сопровождающегося отеком макулы вследствие повышенной экспрессии VEGF-A
US20180264049A1 (en) * 2017-03-20 2018-09-20 Batu Biologics, Inc. Immunotherapy of Aberrant Ocular Angiogenesis by Placental Vaccination
KR20200015523A (ko) * 2017-05-05 2020-02-12 웬델린 데일리 유전자의 노린 유도 발현 및 질환을 치료하기 위한 이의 용도
WO2019126401A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
WO2019126399A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
KR102096509B1 (ko) * 2018-03-28 2020-04-03 재단법인 대구경북과학기술원 항-Tspan12 항체 또는 그의 항원-결합 단편, 및 그의 용도
US11905336B2 (en) 2018-09-10 2024-02-20 Lung Therapeutics, Inc. Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
WO2020149593A2 (ko) * 2019-01-14 2020-07-23 황인후 테트라스파닌-2 억제제를 유효성분으로 포함하는 류마티스 관절염 예방, 개선 또는 치료용 조성물
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3171266A1 (en) * 2020-03-09 2021-09-16 Kimberly Drenser Norrin regulation of plasmalemma vesicle-associated protein and use to treat macular degeneration
EP4229091A1 (en) * 2020-10-15 2023-08-23 The Regents of the University of California Anti-cancer inhibitory antibodies
WO2023155144A1 (en) * 2022-02-18 2023-08-24 Tsinghua University Methods for regulating angiogenesis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US20050181478A1 (en) * 1998-09-01 2005-08-18 Baker Kevin P. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
CA2476120A1 (en) * 2002-02-14 2003-08-21 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods and compositions for the treatment of eye diseases
JP4095498B2 (ja) * 2003-06-23 2008-06-04 株式会社東芝 磁気ランダムアクセスメモリ、電子カードおよび電子装置
AU2006255686A1 (en) * 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
BRPI0716424B8 (pt) * 2006-08-07 2021-05-25 Regeneron Pharma uso do antagonista de ligante delta-like 4 (dll4)
CA2862422A1 (en) * 2012-01-18 2013-07-25 Genentech, Inc. Anti-lrp5 antibodies and methods of use

Also Published As

Publication number Publication date
WO2010030813A2 (en) 2010-03-18
RU2530583C2 (ru) 2014-10-10
WO2010030813A3 (en) 2010-09-30
US20150093375A1 (en) 2015-04-02
IL233390A0 (en) 2014-08-31
JP2015164918A (ja) 2015-09-17
SG193209A1 (en) 2013-09-30
CN102149728A (zh) 2011-08-10
CL2011000513A1 (es) 2012-02-24
AU2009291747A1 (en) 2010-03-18
US20100129375A1 (en) 2010-05-27
IL211279A (en) 2015-03-31
AU2009291747B2 (en) 2016-05-26
RU2014129316A (ru) 2016-02-10
ZA201101202B (en) 2015-08-26
KR20110051245A (ko) 2011-05-17
JP2012502106A (ja) 2012-01-26
IL211279A0 (en) 2011-04-28
CN104306967A (zh) 2015-01-28
CN102149728B (zh) 2014-10-15
CA2734694A1 (en) 2010-03-18
BRPI0913476A2 (pt) 2015-12-01
MX2011002418A (es) 2011-04-05
RU2011113854A (ru) 2012-10-20
EP2334702A2 (en) 2011-06-22
JP5859307B2 (ja) 2016-02-10
US20120276083A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
HK1204274A1 (zh) 抑制眼部血管生成的方法
EP2420493A4 (en) HALOALKYLSULFONANILIDE DERIVATIVES
EP2376493A4 (en) DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE
EP2380877A4 (en) PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
HK1158189A1 (zh) 嗎福啉基嘌呤衍生物
PT2433940E (pt) Derivado de espiroimidazolona
PL2397480T3 (pl) Pochodna diazepinodionu
EP2269993A4 (en) 2-aminoquinazoline DERIVATIVE
IL208623A0 (en) Cyclopentylacrylamide derivative
ZA201005769B (en) Bicycloamine derivative
EP2401281A4 (en) PYRIMIDINPYRIMIDOINDAZOLDERIVAT
HK1174621A1 (zh) -羥基嘧啶- -甲醯胺衍生物
HK1149205A1 (en) Methods for inhibiting angiogenesis using egfl8 antagonists
ZA201006992B (en) Hydroxyquinoxalinecarboxamide derivative
EP2476682A4 (en) 8-oxodihydropurine DERIVATIVE
EP2463290A4 (en) THIENOXAZEPINDERIVAT
EP2248811A4 (en) 2-OXOCHROMENE DERIVATIVE
IL212683A0 (en) Biphenylacetamide derivative
EP2192904A4 (en) METHODS OF INHIBITING TGF-
EP2328892A4 (en) Oxo-tetrahydrofuran-2-YL-benzimidazole derivative
HK1206742A1 (zh) 氨基亞丙基衍生物
AU323246S (en) Coffeemachine for coffeepods
EP2497764A4 (en) DIPHENYLNAPHTYLAMINE DERIVATIVE